Document is current

Article History

Received: 27 March 2020

Accepted: 12 May 2020

First Online: 28 May 2020

Ethics approval and consent to participate

: This was a phase I open-label non-randomized single arm study of neoadjuvant rituximab in patients with high-risk PCa who were candidates for radical prostatectomy (“PROTUX” NCT01804712). The study was conducted in accordance with principles of the Declaration of Helsinki, in compliance with Good Clinical Practice (GCP), and approved by the University of California, San Diego institutional review board (IRB protocol #121451). All patients signed informed consent form.

: No individual person’s data or personal health information in any form is used, therefore, individual consents are not applicable for this manuscript.

: CJ reports investigator-initiated project funding from Calibr, Inc., Astellas, Medivation, and Pfizer outside the submitted work. SH is a Member, Board of Directors, Abeona Therapeutics (ABEO), Member, Scientific Advisory Committee, Aptose Biosciences and has Equity ownership in Abeona Therapeutics, InhibRx and Aptose Biosciences all outside the submitted study. CK reports being on the Scientific advisory board and having stock ownership in Stratify genomics; Jansen Pharmaceuticals; research support and scientific advisory board, Dendreon Inc; scientific advisory board all activities were outside the submitted work. All other authors declare no competing interests related to this study.